Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-RESCUE: Zepatier, Sofosbuvir, and Ribavirin in NS5A-Experienced HCV
NCT03105349Phase 4Withdrawn
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- Jul 2017
- Primary completion
- Dec 2017
- Countries
- 1
01
Overview
Phase 4, open-label trial of elbasvir + grazoprevir in hepatitis C virus infection, sponsored by Fundación SEIMC-GeSIDA. Primary endpoint: Sustained Virologic Response at 12 weeks post-treatment. Planned start Jul 2017; status: withdrawn.
02
Drugs
elbasvir + grazoprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT03105349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03105349.